Psyence Group’s Post

Report from Benzinga's Juan Agustín Spinelli shares happy landmark reached in Psyence Biomedical Ltd's trajectory as the first life science biotechnology company developing nature-derived (non-synthetic) psilocybin mushroom-based psychedelic medicine to be listed on the NASDAQ. https://lnkd.in/ephrFpVq